Strumento inattivo

Altre lingue Immune Therapeutics, Inc. Other OTC

Azioni

IMUN

US45252A1079

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Biostax Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	20/05
Biostax Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	16/04
Biostax Corp. to Participate in U.S. Business Action to End HIV Annual Coalition Meeting and World AIDS Day Reception	30/11
Biostax Announces a Director Appointment of Influential Business Leader Craig Suro	15/11
Biostax Corp. Appoints Craig Suro as a Director	15/11
Biostax Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Biostax Corp. Appoints Mary Clay Caperton to its Board of Directors	02/11
Biostax Announces the Appointment of Ms. Mary Clay Caperton to its Board of Directors	02/11
Biostax Announces FINRA Approval for Name and Ticker Symbol Change, Signals Entry into Global Substance Abuse Commercial Markets and Pioneering HIV Treatment	24/10/23
Immune Therapeutics, Inc. will Change its Name to Biostax Corp	05/10/23
Biostax Corp Announces the Passing of Esteemed Director, H. Louis Salomonsky	14/09/23
Immune Therapeutics, Inc. Announces CEO Changes	13/09/23
Immune Therapeutics, Inc. Announces Management Changes	13/09/23
Biostax Corp. Signs Collaboration Agreement with Immgenuity, Inc. to Pursue Remission in HIV	29/08/23
Biostax Corp. Signs Collaboration Agreement with Immgenuity, Inc. to Pursue Remission in HIV	29/08/23
Immune Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	18/08/23
Biostax Corp Announces the FDAs Acceptance of Three Investigational New Drug Applications (IND) Transfers for JKB-122 for the Treatment of NASH, NAFLD and AIH	15/08/23
Immune Therapeutics, Inc. Announces the Fdas Acceptance of Three Investigational New Drug Applications Transfers for Jkb-122 for the Treatment of Nash, Nafld and Aih	15/08/23
Biostax Launches Growth Funding Round to Revitalize Affordable Healthcare	30/05/23
Biostax Corp. announced that it expects to receive $12 million in funding from DealBox, Inc	30/05/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Immune Therapeutics, Inc. Other OTC

Azioni

IMUN

US45252A1079

Altre lingue

Filtri